MicuRx(SH:688373) Xin Lang Zheng Quan·2025-09-01 02:16Group 1 - The core viewpoint of the news is that Mengke Pharmaceutical has shown significant trading activity and financial performance, with a focus on its stock performance and financing status [1][2] Group 2 - On August 29, Mengke Pharmaceutical's stock increased by 0.84%, with a trading volume of 103 million yuan. The financing buy-in amount was 8.6848 million yuan, while the financing repayment was 8.2656 million yuan, resulting in a net financing buy-in of 419,300 yuan [1] - As of August 29, the total financing and securities balance for Mengke Pharmaceutical was 89.2022 million yuan, accounting for 2.36% of its market capitalization, which is above the 90th percentile level over the past year [1] - The company has no short-selling activity on August 29, with a short-selling balance of 0 shares, indicating a high level of confidence among investors [1] Group 3 - As of June 30, the number of shareholders for Mengke Pharmaceutical was 14,400, an increase of 14.23% compared to the previous period. The average circulating shares per person decreased by 12.45% to 25,342 shares [2] - For the first half of 2025, Mengke Pharmaceutical reported a revenue of 66.9698 million yuan, representing a year-on-year growth of 10.26%. However, the net profit attributable to the parent company was -139 million yuan, which is a 31.11% increase in losses compared to the previous year [2] - As of June 30, 2025, one of the top ten circulating shareholders, Huatai-PineBridge Healthcare Service Flexible Allocation Mixed A (001417), has exited the list [2]